1. Most Discussed
  2. Gainers & Losers
KZA 42.0¢

timetable for aacr conference

  1. dkguinan

    426 Posts.

    Late Breaking Clinical Trial Results of Investigational Anti Cancer Drug Phenoxodiol Among Four Abstracts to be Presented at American

    3/26/04 8:58am

    WASHINGTON, March 26 /PRNewswire-FirstCall/ -- Marshall Edwards, Inc. ( Nasdaq: MSHL), confirmed today that four abstracts, including two from clinical trials on its investigational anti-cancer drug phenoxodiol, are to be presented at the 95th Annual Meeting of the American Association for Cancer Research ( AACR) in Orlando, Florida, March 27-31, 2004, Orange County Convention Center. The abstracts for these presentations are available from AACR, which can be obtained using the information below.

    *Late-breaking entry: Interim Results of a Phase Ib/IIa Study of Oral
    Phenoxodiol in Patients with Late-Stage, Hormone-Refractory Prostate Cancer
    Abstract No. LB-214
    Late-Breaking Abstracts: Poster Session 2
    Tuesday 3/30/04 1:00 p.m. - 5:00 p.m.
    Hall B4-D

    Phenoxodiol phase Ib/II study in patients with recurrent ovarian cancer that are resistant to greater than or equal to second line chemotherapy

    Abstract No. 4457:
    Poster Session
    Tuesday 3/30/2004
    1:00 PM-5:00 PM
    Hall B4-D

    Phenoxodiol a chemosensitizer in taxotere-resistant ovarian cancer cells Abstract No. 4885:

    Poster Session
    Wednesday 3/31/2004
    8:00 AM-12:00 PM
    Hall B4-D

    Phenoxodiol, a novel isoflavone, promotes g1/s arrest by upregulation of p21 in head and neck squamous and salivary gland carcinoma cell lines Abstract No. 1515:

    Sunday 3/28/2004
    2:00 PM-5:30 PM
    Hall F1-2

    Phenoxodiol works by removing the proteins (XIAP, c-FLIP) within the cancer cell that are responsible in large part for preventing the ability of the cancer cell to be killed by the body and by chemotoxic drugs. When these proteins are removed, the cancer cell is sensitive to the body's normal defense mechanisms that are designed to eliminate cancerous cells. This synergistic mechanism also leads to phenoxodiol enhancing in a very potent way the sensitivity of cancer cells to the killing ability of standard anti-cancer drugs, as well as reversing chemo-resistance in cancer cells and restoring their sensitivity to those standard drugs. Phenoxodiol is an investigational drug and has not yet been approved for marketing in the U.S.

    Marshall Edwards, Inc., manages its international research and development programs using the expertise and clinical research capabilities of universities and hospitals in the U.S., Australia and Europe.

    Marshall Edwards, Inc., has licensed rights to bring phenoxodiol to market globally from its parent company, Novogen Limited. (Nasdaq: NVGN). Novogen is developing a range of therapeutics across the fields of oncology, cardiovascular disease and inflammatory diseases based on its phenolic drug technology platform.

    More information on phenoxodiol and on the Novogen group of companies can be found at www.marshalledwardsinc.com and www.novogen.com.

    Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

    SOURCE Marshall Edwards, Inc.
    /CONTACT: United States: David Sheon, +1-202-518-6384, for Marshall
    Edwards, Inc.; or Australia: Christopher Naughton of Marshall Edwards, Inc.,
    +011 61 2 9878 0088/
    /Web site: http://www.marshalledwardsinc.com

Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.


Thank you for visiting HotCopper

We have detected that you are running ad blocking software.

HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.